# A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

> **NCT07072169** · PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 56 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** ABO2203 Injection

## Key facts

- **NCT ID:** NCT07072169
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2026-06
- **Final completion:** 2027-05
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07072169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07072169, "A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07072169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*